Baxdrostat: A New Blood Pressure Drug Class Nears FDA Approval

For patients whose blood pressure refuses to budge despite three, four, or even five medications, the treatment landscape has barely changed in a generation. The last truly novel class of antihypertensive entered clinical practice more than two decades ago. Now, a selective aldosterone synthase inhibitor called baxdrostat is on the cusp of breaking that drought. With the U.S. Food and Drug Administration granting Priority Review and a decision expected in the second quarter of 2026, baxdrostat could become the first drug of its kind to reach patients — and a meaningful advance for the millions living with resistant hypertension.

A Global Health Crisis Hiding in Plain Sight

Hypertension is both ubiquitous and stubbornly undertreated. According to the World Health Organization, an estimated 1.4 billion adults aged 30–79 lived with hypertension in 2024, yet only approximately 320 million — roughly 23% — had the condition under control. Some 600 million did not even know they had it.

Within that vast population sits a particularly challenging subset: patients with resistant hypertension, defined as blood pressure that remains above target despite concurrent use of three or more antihypertensive agents, including a diuretic. A PLOS Medicine editorial notes that up to 30% of patients with resistant hypertension harbor primary aldosteronism — excess aldosterone production that drives sodium retention and vascular stiffness. For these patients, the hormone aldosterone is a central villain, and existing therapies do not adequately address it.

Spironolactone, a mineralocorticoid receptor antagonist, can help but comes with baggage. Clinician concerns about hyperkalemia and antiandrogenic side effects — including breast tenderness and sexual dysfunction — mean the drug is widely under-prescribed. According to the same PLOS Medicine analysis, approximately 10% of patients with resistant hypertension in one cohort proved intolerant of spironolactone altogether. A new strategy for tackling aldosterone-driven hypertension has been a longstanding unmet need.

A Different Angle of Attack: Blocking Aldosterone at the Source

Baxdrostat takes a fundamentally different approach from spironolactone. Rather than blocking the mineralocorticoid receptor downstream — after aldosterone has already been produced — baxdrostat inhibits the CYP11B2 enzyme (aldosterone synthase) responsible for manufacturing aldosterone in the first place. As described in a comprehensive review published in Biomolecules, this upstream intervention reduces circulating aldosterone levels in a dose-dependent manner while preserving cortisol production.

That selectivity is the crucial breakthrough. The CYP11B2 enzyme shares more than 90% sequence similarity with CYP11B1 (11β-hydroxylase), the enzyme responsible for cortisol synthesis. Earlier attempts to develop aldosterone synthase inhibitors stumbled on this problem. According to the same Biomolecules review, the first-generation compound LCI699 "unintentionally inhibited cortisol synthesis" and demonstrated "inferior efficacy when compared to eplerenone." A second-generation candidate, LY3045697, showed improved specificity but "its potency was found to be insufficient, requiring higher doses."

Baxdrostat's active metabolites are, as the review describes, "greatly selective towards aldosterone synthase over 11β-hydroxylase," enabling meaningful aldosterone suppression without the cortisol disruption that doomed its predecessors. With an approximately 29-hour half-life — per the Biomolecules review — once-daily dosing is practical. By sidestepping the mineralocorticoid receptor entirely, baxdrostat also avoids the antiandrogenic and progestogenic side effects that limit spironolactone's use.

BaxHTN: The Phase 3 Evidence

The pivotal BaxHTN trial, published in the New England Journal of Medicine and available through PMC, provides the clinical foundation for the FDA application. It was a Phase 3, multicenter, randomized, double-blind, placebo-controlled study conducted across 214 sites. Investigators enrolled the trial between November 2023 and February 2025, screening 2,591 patients and ultimately randomizing 796.

Participants were adults with hard-to-control hypertension — 73% met criteria for resistant hypertension, and 27% had uncontrolled hypertension on two or more medications. Baseline seated blood pressure averaged 149/87 mmHg. Mean age was approximately 60.8 years, and 62% were male. They were randomized to baxdrostat 1 mg, baxdrostat 2 mg, or placebo, taken once daily for 12 weeks on top of their existing antihypertensive regimen.

The Primary Result

At week 12, the PMC-published results showed that baxdrostat 2 mg reduced mean seated systolic blood pressure by 15.7 mmHg from baseline, compared with a 5.8 mmHg reduction with placebo — yielding a placebo-adjusted difference of 9.8 mmHg (95% CI, –12.6 to –7.0; P<0.0001). The 1 mg dose produced a 14.5 mmHg reduction from baseline, or 8.7 mmHg placebo-adjusted (95% CI, –11.5 to –5.8; P<0.0001).

These reductions are clinically significant. As noted in the Biomolecules review, a 10 mmHg reduction in systolic blood pressure is associated with a 27–41% reduction in stroke risk and a 28% reduction in heart failure risk. Baxdrostat at the 2 mg dose approaches that threshold even after accounting for placebo response.

Blood Pressure Control Rates

Beyond average reductions, the proportion of patients achieving blood pressure control (systolic BP below 130 mmHg) told a compelling story. Per the PMC data, 40.0% of patients on baxdrostat 2 mg reached this target at week 12, compared with 18.7% on placebo — an odds ratio of 2.9. For a population that had failed to achieve control on multiple existing drugs, more than doubling the control rate represents a substantial clinical gain.

Durability Confirmed by Withdrawal

The trial included a randomized withdrawal phase (weeks 24–32) that tested whether the benefit persisted. Among patients who had responded to baxdrostat 2 mg and were then re-randomized, those continuing on baxdrostat maintained a further 3.7 mmHg reduction, while those switched to placebo experienced a 1.4 mmHg increase — a statistically significant difference of 5.1 mmHg (P=0.0016). This withdrawal design provides confidence that baxdrostat's effect is genuine and sustained, not a transient phenomenon.

The Safety Trade-Off: Potassium and Kidney Function

No blood pressure drug is free of side effects, and baxdrostat is no exception. The primary safety signal involves electrolyte shifts — a predictable consequence of suppressing aldosterone, whose physiological role includes regulating potassium excretion.

According to the BaxHTN safety data, serum potassium exceeded 5.5 mmol/l in 11.1% of patients on baxdrostat 2 mg versus 0.4% on placebo. Hyperkalemia requiring clinical intervention occurred in 7.9% of the 2 mg group compared with 0% in the placebo group. However, only 1.5% of 2 mg patients discontinued due to hyperkalemia, suggesting that most elevations were manageable with monitoring and dose adjustment.

Hyponatremia (sodium below 135 mmol/l) was also more common — 22.8% with baxdrostat 2 mg versus 7.0% with placebo — per the same dataset. Cases requiring intervention were infrequent: 2.3% versus 0.4%.

The kidney function data warrants attention. Mean estimated glomerular filtration rate (eGFR) declined by 6.9 ml/min/1.73m² with baxdrostat 2 mg over 12 weeks, compared with essentially no change (–0.1) in the placebo group, per the PMC data. An eGFR decline exceeding 30% occurred in 15.6% of baxdrostat 2 mg patients versus 1.5% on placebo. Whether this reflects hemodynamic changes (reversible) or structural kidney effects (concerning) will require longer-term follow-up.

Overall adverse event rates were similar across groups — 44.7% with baxdrostat 2 mg versus 41.3% with placebo — according to the trial data. There were no deaths in either baxdrostat group. Reported side effects were mostly mild, including headache, nasopharyngitis, and diarrhea.

From CinCor to AstraZeneca: The Commercial Path

Baxdrostat's journey to near-approval has not been a straight line. Originally developed by CinCor Pharma, the drug attracted AstraZeneca's attention following the positive Phase 2 BrigHTN results. According to Longevity Technology, AstraZeneca acquired CinCor in February 2023 for $0.5 billion contingent upon NDA submission — a bet on the Phase 3 program that has now paid off in the form of an accepted application.

The BrigHTN Phase 2 trial, enrolling 275 patients with resistant hypertension, had shown a placebo-adjusted systolic BP reduction of 11.0 mmHg at the 2 mg dose (95% CI, –16.4 to –5.5; P<0.001), according to the Biomolecules review. The larger BaxHTN trial confirmed this signal, albeit with a somewhat smaller placebo-adjusted effect — a common pattern as trials grow larger and more heterogeneous.

Sharon Barr, AstraZeneca's Executive Vice President, framed the significance: "The substantial reduction in systolic blood pressure seen in the BaxHTN trial underscores baxdrostat's novel mechanism and potential to advance treatment for hard-to-control hypertension after limited progress in over two decades," as quoted by Longevity Technology.

AstraZeneca's broader baxdrostat program extends beyond resistant hypertension. According to the Biomolecules review, ongoing trials include BaxAsia (326 patients primarily from Asia), a Phase 2 study in patients with chronic kidney disease, and a Phase 3 trial combining baxdrostat with dapagliflozin in CKD patients with hypertension. Longevity Technology reports that the global program spans over 20,000 patients across multiple studies.

The Competitive Landscape and Barriers Ahead

Baxdrostat is not the only aldosterone synthase inhibitor in development. The PLOS Medicine editorial identifies four compounds in the class — baxdrostat, lorundrostat, dexfadrostat, and vicadrostat — with baxdrostat and lorundrostat furthest along. The editorial places ASIs' placebo-adjusted blood pressure lowering at 7–12 mmHg across programs, "squarely in the range of the most effective antihypertensive drug classes currently in use."

Yet the editorial also flags significant adoption barriers. Generic spironolactone costs pennies on the dollar compared with what a branded first-in-class therapy will likely command. Prior authorization hurdles, lack of cardiovascular outcome data, and the need for potassium monitoring could all slow uptake. Payors will want to see not just blood pressure numbers, but evidence that baxdrostat reduces heart attacks, strokes, and kidney disease progression — outcomes that require larger, longer trials.

There is also the question of genetic variability. The Biomolecules review raises concerns about baxdrostat's efficacy in patients with CYP11B2 genetic polymorphisms that vary across ethnic groups. The BaxAsia trial may help address whether the drug performs consistently across diverse populations, but comprehensive pharmacogenomic data remains limited.

Implications: What an FDA Approval Would Mean

If the FDA grants approval in Q2 2026, baxdrostat would be the first genuinely new mechanism of action for blood pressure treatment since the introduction of direct renin inhibitors — and arguably the most clinically impactful new class since angiotensin receptor blockers entered widespread use.

For cardiologists and primary care physicians managing resistant hypertension, baxdrostat would offer a targeted option for patients with aldosterone-driven disease who cannot tolerate or do not respond to spironolactone. The upstream mechanism — blocking aldosterone production rather than its receptor — represents a conceptual shift that could reshape treatment algorithms.

For the broader hypertension population, the significance extends beyond one drug. Baxdrostat validates the aldosterone synthase inhibition approach after decades of failed attempts, potentially opening the door for the other ASIs in the pipeline. If competition drives prices down and outcome trials confirm long-term benefits, this drug class could eventually serve a far wider patient population than the resistant hypertension niche where baxdrostat will likely launch.

The eGFR decline and hyperkalemia signals will be key areas to watch. Regulatory labeling will likely mandate potassium monitoring, and post-marketing surveillance will need to establish whether kidney function changes are reversible. These are manageable concerns, but they underscore that baxdrostat is not a set-and-forget medication — it requires the kind of attentive clinical follow-up that many stretched healthcare systems struggle to provide.

Key Takeaways

• First-in-class mechanism: Baxdrostat inhibits aldosterone synthase (CYP11B2), blocking aldosterone production upstream rather than blocking its receptor — a new approach after more than two decades without a novel antihypertensive drug class.
• Clinically meaningful efficacy: The BaxHTN Phase 3 trial showed a placebo-adjusted systolic blood pressure reduction of 9.8 mmHg at the 2 mg dose in patients with hard-to-control hypertension, with 40% achieving BP control versus 18.7% on placebo.
• Manageable but real safety signals: Hyperkalemia, hyponatremia, and eGFR decline are dose-dependent side effects that will require monitoring — particularly the 11.1% rate of potassium above 5.5 mmol/l at the 2 mg dose.
• FDA decision imminent: Priority Review status with a PDUFA target in Q2 2026 means an approval decision could come within months.
• Broader pipeline emerging: Baxdrostat is the lead candidate in a class of four ASIs, with ongoing trials in Asian populations, chronic kidney disease, and combination therapy — spanning over 20,000 patients globally.